Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17765327 | 0.87 | GAA (0.36) | SMN1; SMN2MEN1KMT2AGAAKDM4E | |
| SCHEMBL19031895 | 0.85 | CNR2 (0.38) | SMN1; SMN2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL17318002 | 0.85 | SMN1; SMN2 (0.36) | SMN1; SMN2MEN1KMT2AGAAMAPT | |
| SCHEMBL17768392 | 0.82 | KDM4E (0.37) | SMN1; SMN2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL17765122 | 0.82 | KCNJ11 (0.34) | SMN1; SMN2ALDH1A1HPGDSLC22A12GABRA5 | |
| SCHEMBL17318012 | 0.81 | KMT2A (0.34) | SMN1; SMN2MEN1KMT2AGAAKDM4E | |
| SCHEMBL17318022 | 0.81 | MAPT (0.42) | SMN1; SMN2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL18982196 | 0.81 | CYP4F2 (0.43) | SMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL16797511 | 0.78 | FBP1 (0.39) | SMN1; SMN2MEN1KMT2AGAAMAPT | |
| SCHEMBL161047 | 0.76 | MAPT (0.42) | SMN1; SMN2MEN1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310782-B1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3310782-B1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3079701-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3079701-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3303342-B1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3303342-B1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | MERCK SHARP & DOHME CORP. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | MERCK SHARP & DOHME CORP. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3152214-B1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2020-01-29 | — | — | EP | disclosed |
| EP-3152214-B1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2020-01-29 | — | — | EP | disclosed |
| US-20160304536-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3079701-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160145272-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160145272-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2016081668-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016081668-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2015187470-A1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187470-A1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015088885-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015088885-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304536-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, PRKG1 | SMN1; SMN2 691/4885MEN1 1241/4885KMT2A 4673/4885 |
| US-20160145272-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3A, PDE2A, PDE3B | SMN1; SMN2 1602/4885MEN1 2292/4885KMT2A 4660/4885 |
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | GUCY1B1, GUCY1A1, GUCY1A2 | SMN1; SMN2 1314/4885MEN1 2799/4885KMT2A 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.